Analysis of the profile of immune cells, cytokines and chemokines in previously untreated patients with hemophilia

被引：0
|
作者：
Jardim, L. [1 ]
Chaves, D. G. [2 ]
Cerqueira, M. H. [3 ]
Prezoti, A. [4 ]
Lorenzato, C. S. [5 ]
Portugal, M. S. [6 ]
Rezende, S. M. [1 ]
机构：
[1] Univ Fed Minas Gerais, Fac Med, Med Clin, Belo Horizonte, MG, Brazil
[2] Hemominas, Pesquisa, Belo Horizonte, MG, Brazil
[3] Hemorio, Rio De Janeiro, Brazil
[4] Hemoes, Vitoria, Brazil
[5] Hemepar, Curitiba, Parana, Brazil
[6] Hemominas, Belo Horizonte, MG, Brazil
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO034-WED
引用
收藏
页码：766 / 766
页数：1
相关论文
共 50 条
  • [31] Is it dangerous to treat previously untreated patients with severe hemophilia A with recombinant factor VIII concentrates?
    Drillaud, Nicolas
    Lienhart, Anne
    Babuty, Antoine
    Dargaud, Yesim
    Chamouard, Valerie
    Trossaert, Marc
    Fouassier, Marc
    Rugeri, Lucia
    Sigaud, Marianne
    Lefranc, Carole
    Ternisien, Catherine
    Meunier, Sandrine
    HAEMOPHILIA, 2020, 26 : 67 - 67
  • [32] Clinical evaluation of a recombinant factor VIII preparation (Kogenate) in previously untreated patients with hemophilia A
    Yoshioka, A
    Fukutake, K
    Takamatsu, J
    Shirahata, A
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2003, 78 (05) : 467 - 474
  • [33] Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia
    Hill, Brian T.
    Kalaycio, Matt
    ONCOTARGETS AND THERAPY, 2015, 8 : 2391 - 2397
  • [34] Lack of immune response to mouse IgG in previously untreated hemophilia A and hemophilia B patients treated with monoclonal antibody purified factor VIII and factor IX preparations.
    Davis, HM
    Clymer, MD
    Nash, DW
    Frigo, ML
    BLOOD, 1995, 86 (10) : 3460 - 3460
  • [35] A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial
    Carcao, Manuel
    Schiavulli, Michele
    Kulkarni, Roshni
    Rendo, Pablo
    Foster, Meredith
    Santagostino, Elena
    Casiano, Sandra
    Koenigs, Christoph
    BLOOD ADVANCES, 2024, 8 (06) : 1494 - 1503
  • [36] Inhibitors in previously untreated patients (PUPS) with severe hemophilia A: a follow-up cohort study
    Mancuso, M. E.
    van den Berg, H. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 846 - 846
  • [37] Inhibitor incidence in an unselected cohort of previously untreated patients with severe hemophilia B: a PedNet study
    Male, Christoph
    Andersson, Nadine G.
    Rafowicz, Anne
    Liesner, R. I.
    Kurnik, Karin
    Fischer, Kathelijn
    Platokouki, Helen
    Santagostino, Elena
    Chambost, Herve
    Nolan, Beatrice
    Koeigs, Christoph
    Kenet, Gili
    Ljung, Rolf
    van den Berg, H. Marijke
    HAEMATOLOGICA, 2021, 106 (01) : 123 - 129
  • [38] Factor VIII prophylaxis and inhibitor development in previously untreated patients with severe hemophilia A: the RODIN study
    Gouw, S. C.
    Van den Berg, M.
    Auerswald, G.
    Carcao, M.
    Chalmers, E.
    Chambost, H.
    Fischer, K.
    Kurnik, K.
    Liesner, R.
    Petrini, P.
    Platokouki, H.
    Altisent, C.
    Oldenburg, J.
    Nolan, B.
    Perez Garido, R.
    Rafowicz, A.
    Williams, M.
    Van der Bom, J. G.
    HAEMOPHILIA, 2012, 18 : 3 - 4
  • [39] Current Study Data support Evidence for Elocta® and Alprolix® in previously untreated Patients with Hemophilia A and B
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2021, 48 (03)
  • [40] Inhibitor development, safety, and efficacy of Advate® in previously untreated patients with hemophilia A in a postmarketing surveillance in Japan
    Taki, Masashi
    Fukutake, Katsuyuki
    Matsushita, Tadashi
    Nogami, Keiji
    Shima, Midori
    Yoshioka, Akira
    Takamatsu, Junki
    Arai, Morio
    Takagi, Hiroshi
    Uchikawa, Haruhiko
    Engl, Werner
    Shirahata, Akira
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 109 (01) : 70 - 78
12345